Wall Street Zen Downgrades National Research (NASDAQ:NRC) to Hold
Wall Street Zen has downgraded National Research (NASDAQ:NRC) from "Buy" to "Hold," following a separate downgrade to "Sell" by Weiss Ratings. Despite these downgrades, MarketBeat's consensus rating remains "Hold" with a $26.00 price target. National Research recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
National Research Corporation (NRC) stock price, news, quote and history
This article provides a detailed overview of NRC Health (NRC) stock, including its current price, historical data, key financial metrics, and analyst ratings. It highlights the company's services in healthcare analytics and patient experience improvement, and compares its performance against the S&P 500. The article also includes information about the company's recent earnings, leadership, and industry position.
Record Backlog Powers NRC Health’s (NRC) Upward Potential
Long Cast Advisers, an independent investment adviser, highlighted NRC Health (NASDAQ: NRC) in its Q2 2026 investor letter, noting the company's strong performance, recent management changes, and a record backlog. Despite its positive outlook, the firm suggests that certain AI stocks may offer greater upside potential with less risk. NRC Health provides analytics to healthcare organizations and recently announced its largest contract in company history.
National Research Corp (NRC) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for National Research Corp (NRC), noting its current earnings forecast score is 8.00, ranking 37th in its industry. Based on one analyst's rating, NRC is given a "Buy" recommendation with a target price indicating a 33.54% upside. The report includes peer comparisons but states that relevant financial forecasting data for EPS, Revenue, Net Profit, and EBIT has not yet been disclosed by the company.
National Research (NASDAQ:NRC) Raised to Buy at Wall Street Zen
Wall Street Zen upgraded National Research (NASDAQ:NRC) from "hold" to "buy", contributing to a consensus "Moderate Buy" rating and a $26.00 price target. The company recently exceeded quarterly earnings expectations, reporting $0.31 EPS against a projected loss of $0.15, with revenues slightly above estimates. National Research, a healthcare analytics firm, holds a market capitalization of $443.9 million, with 47.26% of its shares owned by institutional investors.
National Research Corp (NRC) Institutional Confidence
National Research Corp (NRC) has an institutional shareholding score of 5.00, placing it 95th out of 159 in the Professional & Commercial Services industry. The latest institutional shareholding proportion is 53.51%, marking a 9.20% increase quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 860.95K shares, which represents 4.30% of outstanding shares.
National Research Corp (NRC) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article assesses the risk profile of National Research Corp (NRC), highlighting its volatility, financial risk, and investment risk. With a current risk score of 5.22, NRC ranks 89th out of 159 in its industry, suggesting a moderate risk level. The company's beta of 0.37 indicates lower volatility compared to the broader market, tending to underperform in bull markets but experience smaller declines in bear markets.
National Research Q2 Earnings Call Highlights
National Research (NRC Health) reported Q2 results with an 11% year-over-year growth in total recurring contract value (TRCV) to $151.9 million. Revenue increased by approximately 4%, and adjusted EBITDA reached $9.4 million. The company highlighted strategic investments in customer success, product development, and its Governance Institute, alongside the phased implementation of a landmark customer win and growth opportunities in cross-selling and AI integration.
NRC|National Research Corp|Price:22.290|Chg%:+1.020
This article provides a comprehensive stock analysis of National Research Corp (NRC) according to TradingKey's scoring system. It highlights NRC's stable fundamentals, high growth potential, and fair valuation within the Professional & Commercial Services industry. The analysis also notes high institutional ownership and a recent "Buy" rating from analysts with a target price of $23.00, indicating an expected upward trend in the medium term.
Citizens Jmp Forecasts Strong Price Appreciation for National Research (NASDAQ:NRC) Stock
Citizens Jmp has raised its price target for National Research (NASDAQ:NRC) from $23 to $26, maintaining a "market outperform" rating and suggesting a 22.27% potential upside. The company also recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. National Research currently holds a "Moderate Buy" consensus rating among analysts.
National Research Q2 Earnings Call Highlights
National Research (NRC Health) reported strong Q2 results, with a 11% year-over-year growth in total recurring contract value (TRCV) to $151.9 million. Despite a revenue recognition change causing a two-percentage-point headwind, the company saw a 4% revenue increase and maintained a 27% adjusted EBITDA margin. Investments in implementation, customer success, and product development, along with strategic initiatives like cross-selling, The Governance Institute, and AI integration, are set to drive future growth.
National Research (NASDAQ:NRC) Hits New 12-Month High Following Earnings Beat
National Research (NASDAQ:NRC) reached a new 52-week high after reporting better-than-expected quarterly earnings, with EPS of $0.31 surpassing estimates by $0.46 and revenue of $35.39 million also exceeding expectations. The company maintains a "Moderate Buy" consensus rating among analysts, with an average price target of $23.00, and institutional investors hold a significant stake of 47.26%. National Research specializes in healthcare analytics, providing performance-improvement tools to over 1,600 hospitals and 12,000 care sites.
National Research Corp (NRC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for National Research Corp (NRC), noting its current valuation score of 7.97, which ranks 114 out of 160 in the Professional & Commercial Services industry. The company's current P/E ratio is 53.13, falling below its recent high but significantly above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
NRC|National Research Corp|Price:21.040|Chg%:+0.210
National Research Corp, also known as NRC Health, provides analytics and insights to healthcare organizations in the United States, focusing on patient and employee experience, patient engagement, and customer loyalty. The company offers digital solutions across Patient, Consumer, Employee, and Market Experience categories, which can be implemented individually or as an enterprise solution. This article details the company's background, business scope, key executives, and institutional shareholding data.
National Research Corp (NRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides an overview of National Research Corp's (NRC) financial data, focusing on its revenue breakdown. It details the company's regional revenue contribution, showing that all reported revenue comes from the United States, but notes that full business segment data has not yet been disclosed. The piece includes current stock performance metrics like market cap and P/E ratio.
National Research Corp (NRC) Financial Health: Profitability & Balance Sheet Analysis
National Research Corp (NRC) currently holds a financial score of 7.50, placing it 66th out of 159 in the Professional & Commercial Services industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 3.73% year-over-year increase, while net profit surged by 44.32% year-over-year. Key metrics for financial health, quality of earnings, operational efficiency, growth potential, and shareholder returns are provided with specific scores, though some detailed data points are not yet disclosed.
National Research Corp (NRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of National Research Corp (NRC), highlighting its current price momentum score, support at $19.84, and resistance at $22.62. It details various technical indicators like MACD, RSI, and Moving Averages, offering buy, sell, or neutral signals for investment reference. The analysis concludes with FAQs explaining technical ratings, moving averages, and current signals for NRC.
NRC|National Research Corp|Price:21.510|Chg%:+0.470
National Research Corp (NRC) is trading at $21.290, with a market capitalization of $481.95M. Analysts have given the stock a "Buy" rating with a target price of $23.00, suggesting a 9.32% upside. The company is noted for stable fundamentals, high growth potential, and a high dividend payout ratio, though it faces risks like institutional selling and lower market activity.
National Research Corp (NRC) Income Statement
This article provides a detailed quarterly and annual income statement for National Research Corp (NRC), offering insights into its financial performance, including revenue, expenses, operating profit, and net income. It also includes frequently asked questions about how to interpret the income statement and key financial metrics relevant to NRC stock. The company reported a net income of -3.28M for the latest quarter and 11.29M for fiscal year 2025.
Heartland Advisors Inc. Has $4.03 Million Position in National Research Corporation $NRC
Heartland Advisors Inc. significantly increased its stake in National Research Corporation (NASDAQ:NRC) by 374.3% in the first quarter, bringing its total holdings to 237,147 shares valued at $4.03 million. Other hedge funds also showed increased interest, with institutional investors and hedge funds now owning 47.26% of NRC shares. The company recently reported Q1 earnings of $0.21 per share on $34.8 million revenue, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $23.00.
Charter and bylaw changes follow NRC Health (NRC) 2026 shareholder meeting
NRC Health reported on its 2026 annual stockholder meeting, where shareholders approved amendments to the company's certificate of incorporation, effective June 24, 2026. The board subsequently amended the bylaws to align with these changes. Directors received strong support in their elections, with individual nominees generally receiving about 19.8 million votes in favor.
NRC - Experience Automation And Value-Based Care Tailwinds Will Support A Stronger Long-Term Outcome
NRC Health is positioned for stronger long-term outcomes due to tailwinds in experience automation and value-based care. The company's solutions, which help healthcare organizations improve patient experience and link feedback to outcomes, are in increasing demand. Analysts expect significant revenue and earnings growth for NRC Health over the next three years, with profit margins improving from 6.2% to 13.9%.
National Research Corp (NRC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of National Research Corp (NRC), outlining major institutional and individual holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key entities. The report lists top shareholders like Amandla MK Trust and Common Property Trust LLC, along with the percentage of shares held by different investor types and which ETFs hold NRC stock.
National Research Corp (NRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for National Research Corp (NRC), detailing its financial performance with a focus on regional revenue. It highlights that as of April 6 (updated), the company's revenue from the United States is $137.39 million, while Canada shows no revenue contribution. The article notes that relevant data for business segments and further comparative fiscal years for revenue have not yet been disclosed by the company.
National Research Corp (NRC) Institutional Confidence
National Research Corp (NRC) has an institutional shareholding score of 5.00, ranking 98th out of 161 in its industry. Institutional investors hold 53.51% of its shares, a 9.20% increase quarter-over-quarter. ETHSX is the largest institutional shareholder, with 4.30% of outstanding shares.
National Research Corp (NRC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for National Research Corp (NRC), noting that no earnings forecast score is currently available for the company. It indicates that the Professional & Commercial Services industry average score is 7.67. The report covers basic financial data, including market capitalization and P/E ratio, but states that relevant data for EPS, Revenue, and Net Profit forecasts have not yet been disclosed by the company.
National Research Corp (NRC) Financial Health: Profitability & Balance Sheet Analysis
National Research Corp (NRC) has a current financial score of 7.48, ranking 72 out of 161 in the Professional & Commercial Services industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 3.73% year-over-year increase, with net profit rising by 44.32% year-over-year. Financial data points for specific metrics like cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company.
National Research Corp (NRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of National Research Corp (NRC), detailing its price momentum score, current stock price fluctuations between resistance and support levels, and an evaluation based on various technical indicators and moving averages. While indicators like MACD and RSI suggest neutrality or sell, moving averages show mixed signals, with a slight lean towards buying on longer-term MAs. The overall sentiment from the indicators and moving averages signals a "Sell" for today.
National Research Corp (NRC) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for National Research Corp (NRC), highlighting its volatility, financial risk, and investment risk. NRC has a current risk assessment score of 5.22, ranking 89 out of 161 in the Professional & Commercial Services industry, with a beta of 0.35 indicating lower volatility compared to the S&P 500. The report details various risk metrics including historical returns, maximum drawdown, Sharpe ratio, and liquidity.
How National Research Corporation (NRC) Affects Rotational Strategy Timing
This article analyzes National Research Corporation (NRC) stock, highlighting a weak near-term sentiment potentially challenging long-term strength. It outlines various AI-generated trading strategies including position trading, momentum breakout, and risk hedging, tailored for different risk profiles. The analysis points to an exceptional 65.6:1 risk-reward setup targeting a 17.8% gain with minimal risk, and details multi-timeframe signal analysis with support and resistance levels.
National Research Corp (NRC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of National Research Corp (NRC), highlighting its current valuation score, P/E ratio, and ranking within the Professional & Commercial Services industry. As of June 17, 2026, NRC's valuation score is 8.09, placing it 110 out of 161 in its sector, with a P/E ratio of 44.33. The report notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Responsive Playbooks and the NRC Inflection
The article analyzes National Research Corporation (NYSE: NRC), highlighting strong sentiment across all horizons and an exceptional 66.6:1 risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, with specific entry, target, and stop-loss levels. The analysis emphasizes the company's strong support and resistance signals across near-term, mid-term, and long-term timeframes.
Understanding the Setup: (NRC) and Scalable Risk
This article analyzes National Research Corporation (NYSE: NRC), highlighting strong sentiment across all horizons and an exceptional 67.2:1 risk-reward setup targeting a 19.3% gain. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, along with multi-timeframe signal analysis indicating strong support and resistance levels. The report emphasizes the current AI signals, entry/exit points, and risk management parameters for NRC.
Understanding the Setup: (NRC) and Scalable Risk
This article from Stock Traders Daily discusses National Research Corporation (NYSE: NRC), highlighting strong sentiment across all time horizons and an exceptional 67.2:1 risk-reward setup targeting a 19.3% gain versus 0.3% risk. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, supported by multi-timeframe signal analysis. The piece emphasizes the platform's predictive AI capabilities for optimizing position sizing and minimizing drawdown risk.
TradingKey
This page provides an overview of National Research Corp (NRC) stock on the TradingKey platform. It displays real-time stock data, including its current price, daily change, market cap, and P/E ratio. The article also outlines various sections available for the stock, such as Financials, Discussions, and Analysis.
National Research (NRC) 10K Form and Latest SEC Filings 2026
MarketBeat provides comprehensive information on National Research (NRC)'s SEC filings, highlighting that the company has submitted over 397 documents since 2017. These filings are critical for investors to access verified financial data, including annual 10-K reports, quarterly 10-Q reports, and 8-K current reports. The article details the most recent filings and explains the significance of various SEC document types for investment analysis.
Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Redwood AI's subsidiary has been approved to receive up to C$240,000 in funding from the National Research Council of Canada's Industrial Research Assistance Program for its Q-SAFE project. This initiative focuses on improving hazardous chemical risk classification using AI and quantum-enhanced optimization, with applications in defense, security, and industrial settings. The project aims to enhance chemical data analysis for safer and more reliable screening of hazardous materials, supporting both commercial and public-sector needs.
Outstanding NRC Patient Experience Scores Rank Sanford Bismarck Therapy Team Among Nation’s Best
The therapy team at Sanford Health in Bismarck has achieved exceptional 2025 year-end patient experience results from the National Research Corporation (NRC), ranking among the nation's best. They scored in the 100th percentile for "Staff listens" and high percentiles for "Staff explains" and "Had enough input," reflecting their commitment to compassionate, patient-centered care. These scores highlight the team's dedication to creating a supportive environment where patients feel heard and involved in their care decisions.
National Research (NASDAQ:NRC) Stock Price Crosses Above 200 Day Moving Average - What's Next?
Shares of National Research Corporation (NASDAQ:NRC) crossed above its 200-day moving average on Tuesday, trading as high as $19.31 with a volume of 132,991 shares. The company recently announced a quarterly dividend of $0.16 per share, payable on July 10th to shareholders of record on June 26th, representing an annualized yield of 3.4%. While institutional investors have been adjusting their stakes in NRC, one analyst recently downgraded the stock from "hold" to "sell."
Earnings call transcript: NRC Health Q1 2026 sees growth but cautious market
NRC Health reported its Q1 2026 earnings, showcasing a return to revenue growth for the first time since 2023, with a 4% year-over-year increase to $34.8 million and an EPS of $0.21. The Total Recurring Contract Value (TRCV) reached a record high of $152.1 million, driven by strong sales bookings and an unprecedented landmark deal. Despite these positive financial results and a 60.7% return over the past year, the stock price experienced a slight decline of 1.23% in aftermarket trading, reflecting a cautious investor sentiment. The company anticipates flat adjusted EBITDA margins in Q2 2026 due to implementation costs for the new deal, with expansion expected in Q3 2026.
NRC Health (NRC) Q1 2026 Earnings: GAAP EPS $0.14, Revenue $34.8M -- Is the Stock 26.3% Undervalued?
NRC Health (NRC) reported strong Q1 2026 earnings, with revenue up 4% year-over-year to $34.8 million and GAAP EPS at $0.14. The company achieved a record Total Recurring Contract Value (TRCV) of $152.1 million, reflecting healthy commercial momentum and client engagement. GuruFocus assesses NRC Health as 26.3% undervalued based on its GF Value, with a GF Score of 73/100, indicating above-average potential.
National Research (NASDAQ:NRC) Releases Quarterly Earnings Results
National Research (NASDAQ:NRC) recently announced its quarterly earnings, reporting $0.14 EPS. The company showed strong profitability with a 103.84% return on equity and an 8.44% net margin. Despite positive profitability metrics, the stock experienced a slight dip, trading at $16.88, and received a "Sell" rating from analysts and Weiss Ratings due to weak investor sentiment.
National Research: Q1 Earnings Snapshot
National Research Corp. (NRC) reported a net income of $3.2 million in its first quarter, with earnings of 14 cents per share. Adjusted for non-recurring costs, the company's earnings were 21 cents per share. The healthcare advisor also posted revenue of $34.8 million for the period.
NRC Health lands biggest deal in 45 years as revenue growth returns
NRC Health reported a strong first quarter for 2026, with total revenue rising 4% year-over-year to $34.8 million and Total Recurring Contract Value (TRCV) increasing 13% to $152.1 million. The company secured its largest deal in 45 years, indicating significant momentum and strategic validation. NRC Health also declared a quarterly cash dividend of $0.16 per share, payable on July 10, 2026.
National Research (NASDAQ:NRC) Stock Crosses Above 200 Day Moving Average - Time to Sell?
National Research (NASDAQ:NRC) stock has recently crossed above its 200-day moving average of $16.45, trading as high as $17.60 before settling at $17.11 with a volume of 112,562 shares. Despite this upward movement, Weiss Ratings downgraded the stock to "sell (d+)," and MarketBeat's consensus rating is also "Sell," citing weak liquidity (current and quick ratios 0.55), high leverage (debt-to-equity 5.36), and a P/E of 34.2, even though ROE was 103.8%. Institutional investors have shown mixed activity, with some increasing their stakes while others have remained stable.
70% of hospital boards lack continuing education, NRC report says
A new report by The Governance Institute (TGI), a service of NRC Health, titled "Falling Behind," indicates that hospital governance models are lagging behind the advancements in modern healthcare. The report, released during TGI's 250th Leadership Conference, highlights that roughly 70% of hospital boards lack continuing education requirements and suggests that only a tiny fraction of hospital patient revenue is invested in board development. TGI is introducing a "Governance Trilogy" and forming a Blue-Ribbon Committee to address these gaps and redesign healthcare governance.
NRC Health (Nasdaq:NRC) - Stock Analysis
This report provides a stock analysis of NRC Health (Nasdaq:NRC), highlighting its current market capitalization of US$390.8m and a stock price of US$17.50. The analysis points out that the company is 107.8% overvalued based on fair value estimates and notes risks such as declining earnings, poorly covered dividends, and changes in profit margins. It also includes recent news, performance summaries, and an overview of the company's fundamentals and analyst coverage.
Precision Trading with National Research Corporation (NRC) Risk Zones
Quantitative Research Desk and Thomas H. Kee Jr. provide a detailed analysis of National Research Corporation (NYSE: NRC), highlighting strong sentiment and an exceptional 66.6:1 risk-reward setup. The analysis outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones, supported by multi-timeframe signal analysis.
National Research NRC Q4 2025 Earnings Transcript
National Research (NRC) reported its Q4 and full-year 2025 earnings, showing sequential revenue and Total Recurring Contract Value (TRCV) growth despite a challenging prior year. The company highlighted 99% recurring revenue, a record-high gross dollar retention rate, and significant growth in new sales following a restructured sales approach. Investments in AI-powered features and strategic leadership appointments are expected to drive future growth.
National Research NRC Q4 2025 Earnings Transcript
National Research Corporation (NRC) reported sequential revenue and Total Recurring Contract Value (TRCV) growth in Q4 2025 despite a challenging prior year. The company saw 99% recurring revenue, strong sales growth, and high customer retention, driven by restructured go-to-market strategies and product innovation, including AI-powered features. Management emphasizes continued growth, profitability, and strategic capital allocation for 2026, aiming for margin expansion as revenue recovers.
